FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
The purpose of this study is to evaluate the effects, good and/or bad, of the drug regorafenib with chemotherapy regime (FOLFOX). This is a a Phase II trial that will study if this new treatment is effective and safe in patients with esophagus and stomach cancer.
Esophageal Cancer|Gastric Cancer
DRUG: Regorafenib|DRUG: 5-Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin
Progression Free Survival (PFS), 6 months
Overall Survival (OS), Overall survival will be measured from the start of treatment to death or last follow-up and will be estimated using the Kaplan-Meier method, 2 years|Overall Response Rate, This is defined as the percentage of patients who have achieved either an objective complete or partial target lesion response that is confirmed on the RECIST 1.1 criteria. Complete or partial responses will be confirmed with repeat CT evaluation after 4 weeks., 4 weeks|Participants Evaluated for Toxicity, Adverse events will be determined as per the NCI Common Toxicity Criteria, version 4.0. Toxicity during cycle 1 and subsequent cycles will be reported., 1 year
The purpose of this study is to evaluate the effects, good and/or bad, of the drug regorafenib with chemotherapy regime (FOLFOX). This is a a Phase II trial that will study if this new treatment is effective and safe in patients with esophagus and stomach cancer.